News provided by Novo Nordisk Jul 01, 2026, 07:00 ET Starting today, eligible Medicare patients living with obesity can access Wegovy (semaglutide) injection and pill for a $50 monthly copay Wegovy offers adults living with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major cardiovascular events including death, heart attack, or stroke in adults with obesity and heart disease a claim only Wegovy can make Since launching in January 2026, Wegovy pill has reached 3 million prescriptions * Medicare GLP-1 Bridge participation now expands patient access to authentic, FDA-approved Wegovy , including the Wegovy pill PLAINSBORO, N.J., July 1, 2026 /PRNewswire/ -- Starting today FDA-approved Wegovy (semaglutide) is available through the Medicare GLP-1 Bridge, a new access pathway for millions of older adults living with obesity
The correct blood or urine test depends on the metal and timing of exposure
Increasing adoption of advanced GLP-1 therapies within outpatient settings is accelerating growth
Use body composition, symptoms, nutrition, medications, and labs together instead of relying on one marker
Diepvens, K., Westerterp, K
The prescription medication is a GLP-1 receptor agonist that mimics a naturally occurring hormone in the body
